To further develop, coordinate and manage a sustainable European Standardised Care Network (ESCAN) with broad European coverage providing access to a large population suffering from CA-ARTI across all age groups and different community care settings, differing antimicrobial stewardship programs, country level income and differing levels of outpatient antibiotic use.
To generate clinical evidence about current care and the potential value of clinical algorithms that include one or more CA-ARTI-Dx by benchmarking current clinical practice for CA-ARTI in 20 EU Member states and H2020 Associated Countries selected from our existing COMBACTE, PREPARE, PENTA-ID and LOTTA-Net networks and enhanced with further networks, on the basis of levels of income, variation in antibiotic stewardship programs, and levels of antibiotic prescribing.
To design and implement a novel, robust, flexible and efficient randomised controlled trial of the clinical and costeffectiveness of algorithms including one or more CA-ARTI-Dx for managing CA ARTI in community care in 10 EU Member States and H2020 Associated Countries (selected on the basis of the results of the point prevalence audit survey; PPAS).
https://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.png00melanie.hostehttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngmelanie.hoste2019-09-29 10:13:222019-11-19 10:16:16WP Co-Lead Face-to-Face & Business Plan Meeting
University of Antwerp, bioMérieux, and Wellcome Trust
to coordinate VALUE-Dx, a European Public-Private Partnership
to fight antimicrobial resistance through diagnostics
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226melanie.hostehttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngmelanie.hoste2019-09-26 14:38:492019-09-30 17:10:40Launch of VALUE-Dx
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.